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MODULATION OF ESTROGEN METABOLISM 
AND PREVENTION OF PATHOLOGIES 
Bodhisattwa Mondal, Ph.D. 
University of Nebraska, 2019 
Supervisor: Eleanor G. Rogan, Ph.D. 
Estrogens have been implicated in non-cancerous pathologies such as Fuchs Endothelial 
Corneal Dystrophy (FECD), and accumulating evidence suggests estrogen genotoxicity leads to 
initiation of multiple types of cancer among Caucasian populations. These studies were mono-
racial, and restoration of estrogen metabolism imbalance using naturally occurring compounds 
were not definitive. Therefore, the role of estrogen metabolism in FECD, in cancer initiation among 
African American (AA) populations, its modulation by environmental toxicant arsenic trioxide 
(As2O3), and by antioxidants polydatin (PD) and resveratrol were explored. 
In human breast epithelial non-transformed MCF10A cells, As2O3 – induced cytotoxicity 
was partially ameliorated by 25 μM resveratrol. Both 25 μM resveratrol and As2O3 induced NQO1, 
possibly via Nrf2 stabilization. As2O3 suppressed CYP1B1 expression whereas 25 μM resveratrol 
restored it to basal levels -- rendering the As2O3 + resveratrol combination a little less effective than 
As2O3 alone in lowering estrogen-DNA adduct formation. Therefore, we cannot conclude that 
resveratrol co-treatment with As2O3 has any beneficial roles on estrogen metabolism, although 
resveratrol might provide some chemical protection as well as the protection from As2O3-
cytotoxicity might stem from other cellular pathways. 
PD was found to be safer than resveratrol. In MCF10A cells, PD was found to be less 
efficacious than resveratrol in inducing NQO1 or repressing CYP1B1, although this difference was 
abolished in human prostate epithelial non-transformed RWPE-1 cells – rendering both the 
antioxidants equally effective in lowering estrogen-DNA adduct formation. This indicates PD 
could be a less toxic alternative for resveratrol in chemo-preventing estrogen-induced cancer 
initiation in prostate cells. 
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AA women with breast cancer, and AA men at high risk for or with prostate cancer, 
exhibited higher estrogen-DNA adduct ratios than the controls. This suggests loss of estrogen 
metabolism balance might be instrumental in breast and prostate cancer initiation in AA 
populations. 
In the menadione-induced FECD model of HCEnC-21T cells, N-acetylcysteine (NAC) was 
observed to ameliorate estrogen-DNA adduct formation, and this effect was sustained even in 
NQO1 KO cells. Therefore, NAC can be a promising therapeutic modality for FECD where loss of 
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Estrogen Metabolism and Cancer 
Cancers comprise a spectrum of multifactorial malignant disorders in the body, and the 
causative factors range from diet to lifestyle to environmental pollutants. Following James and 
Elizabeth Miller’s chemical carcinogenesis principles (Miller and Miller, 1981) and observing the 
structural similarity between environmental carcinogens like benzene and polycyclic aromatic 
hydrocarbons (PAHs) and endogenous aromatic compounds like estrogen and dopamine led to the 
search for endogenous carcinogens. Although estrogens have myriad beneficial roles in the body 
including breast (Brisken and O'Malley, 2010) and uterine development (Groothuis et al., 2007), 
bone resorption reduction (Kameda et al., 1997), anti-atherosclerosis (Li et al., 2004) etc., they 
have also been implicated in a number of diseases, including breast (Chlebowski et al., 2003) and 
uterine cancer progression (Grady et al., 1995). Interestingly, studies by Bocchinfuso et al. 
demonstrated tumor development in an estrogen receptor (ER) knock out transgenic mouse model 
of breast cancer; and elimination of estrogen by pre-pubertal ovariectomy increased tumor-free 
survival rates (1999). At the same time, studies by Russo et al. demonstrated that treatment of 
immortalized but non-transformed ER-α negative breast epithelial cells MCF10F with estradiol 
(E2) or 4-OHE2 led to transformation (2003), and inclusion of antiestrogens did not affect the 
observed transformation (Lareef et al., 2005). Such in vitro and in vivo evidence suggests the 
presence of some receptor-independent pathway of cancer initiation, and the central hypothesis of 
our laboratory is that metabolism of estrogens/androgens or environmental estrogenic compounds 
generates catechol quinones that can react with DNA, leading to the formation of apurinic sites, 
which in turn generate mutations, and initiate oncogenic transformation (Fig. 1).  
Mutagenicity of estrogen and its various metabolites has indeed been demonstrated in 
animal models: E2-3,4-Q in the dorsal skin of female SENCAR mice (Chakravarti et al., 2001) and 
E2 and 4-OHE2 in mammary glands of Big Blue® (BB) rats (Cavalieri et al., 2006). Numerous 
epidemiological studies have documented evidence of significantly higher levels of depurinating 
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estrogen-DNA adducts in high-risk groups and cancer patients [Women: breast, both in urine 
(Gaikwad et al., 2009) and serum (Pruthi et al., 2012), ovarian (Zahid et al., 2014), and thyroid 
(Zahid et al., 2013); Men: prostate (Markushin et al., 2006, and Yang et al., 2009), and non-
Hodgkin Lymphoma (Gaikwad et al., 2009)] compared to the levels in healthy controls. This 
indicates estrogen-DNA adduct formation is a not an event associated with cancer promotion, but 


























































Modulation of Estrogen Metabolism 
Evidence suggests the imbalance of estrogen/androgen metabolism in high-risk groups and 
cancer patients can stem from irregular expression patterns of one or more of the four key estrogen-
metabolizing enzymes: aromatase or Cytochrome P450 19 (CYP19), Cytochrome P450 1B1 
(CYP1B1) (and CYP1A1), catechol-O-methyltransferase (COMT), and NADPH Quinone Oxidase 
(NQO1) (Singh et al., 2005). As shown in Fig. 1, a greater activity of aromatase and/ or CYP1B1 
(or CYP1A1) leads to formation of more estrogen-DNA adducts, and hence these two are known 
as activating enzymes. On the other hand, a greater activity of NQO1 and/or COMT leads to 
formation of fewer estrogen-DNA adducts, and hence these two are known as protective enzymes. 
Among these, NQO1 and CYP1B1 (or CYP1A1) are highly inducible. NQO1 has been shown to 
be induced by the Nrf2-Keap1 signaling pathway (Lu et al., 2008). Therefore, compounds that 
stabilize Nrf2 protein and promotes its nuclear translocation can lead to induction of NQO1 
expression and a concomitant decrease in estrogen-DNA adduct formation (Fig. 2). On the other 
hand, CYP1B1 (and CYP1A1) has been shown to be induced by the Aryl Hydrocarbon Receptor 
or AhR signaling pathway (Zahid et al., 2008). Therefore, compounds like 2,3,7,8-
Tetrachlorodibenzo-p-dioxin or TCDD that activate AhR signaling can lead to induction of 
CYP1B1 (and CYP1A1) expression and concomitant increase in estrogen-DNA adduct formation 
(Fig. 2). Taken together, estrogen metabolism is subject to modulation by a variety of chemical 
agents or physical forces like UV, which depending on the protecting or activating enzyme target, 
can either increase or decrease the odds for breast or other cancer initiation. Under such 
circumstances, studying the effects of environmental contaminants like arsenic trioxide in 
modulating estrogen metabolism is important to identify populations disproportionately susceptible 
to estrogen-induced breast and prostate cancer initiation. On the other hand, investigating the 
efficacy of naturally occurring antioxidants like resveratrol or its precursor polydatin (PD) in 
restoring a unbalanced estrogen metabolism can provide mechanistic understanding for use of new 





















Fig. 2. Environmental compounds modulating signal transduction pathways upstream of key 









Polymorphisms in Key Estrogen-Metabolizing Enzymes 
 Among the four key enzymes involved in estrogen metabolism, we observed genetic 
polymorphisms in COMT and CYP1B1, affecting enzymatic stability and/or activity. A guanine-
to-adenine single nucleotide polymorphism (SNP) (SNP ID: rs4680) in the codon 158 of long-chain 
or membrane-bound COMT (MB-COMT) or in the codon 108 of short-chain or soluble COMT (S-
COMT) causes coding of methionine instead of a valine residue, and this is annotated as a 
Val108/158Met substitution. This is a loss-of-function mutation, and individuals homozygous for 
the polymorphic allele (COMTLL or Met/Met) have been reported to have 4 to 5-fold lower activity 
of COMT compared to the same in individuals homozygous for the wild type allele (COMTHH or 
Val/Val) (Porcelli et al., 2011). A lower activity of the protective enzyme COMT would cause 
more estrogen-DNA adduct formation and this might lead to an increased probability of 
tumorigenesis. Although almost a quarter of the Caucasian population in the US report 
homozygosity for the COMTLL allele (Scanlon et al., 1979), epidemiological studies correlating 
this polymorphism with heightened breast cancer risk have been somewhat inconclusive (Yim et 
al., 2001). 
 CYP1B1 is a microsomal monooxygenase that catalyzes the oxidative activation of 
exogenous procarcinogens like polyaromatic hydrocarbons (PAH) and endogenous procarcinogens 
like estrogens. The literature shows several mutations for CYP1B1 gene among populations. A 
cytosine-to-guanine SNP (SNP ID: rs1056836) in the codon 432 causes missense coding of valine 
instead of a leucine residue. This Val432Leu is a gain-of-function mutation, and a higher 4-OHE1: 
2-OHE1 ratio reflecting a higher CYP1B1 activity has been reported among homozygotes for the 
variant allele (Val/Val) compared to the same in wild type carriers (Leu/Leu), and the effects were 
robust enough to be seen in a small sample size of 20 (Paracchini et al., 2005). A higher activity of 
the activating enzyme CYP1B1 would cause more estrogen-DNA adduct formation and this might 
lead to an increased probability of tumorigenesis. On the other hand, an adenine-to-
cytosine/guanine SNP (SNP ID: rs1800440) in the codon 453 of CYP1B1 gene causes another 
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missense mutation, leading to a threonine/serine substitution for asparagine. This Asn453Thr/Ser 
mutation has been correlated with a higher catalytic activity as well as with a lower stability by 
increasing its rate of degradation. This enhanced degradation of CYP1B1 has been postulated to 
exert protection against carcinogenesis (McGrath et al., 2004). 
Studies investigating the correlation between one gene polymorphism and risk of 
carcinogenesis are sometimes inconclusive or might not have enough statistical power. 
Interestingly, one study reported women simultaneously homozygous to polymorphic COMT allele 
(Val108/158Met) and polymorphic CYP1B1 allele (Val432Leu) were six times more likely to have 
ovarian cancer than their counterparts carrying wild type alleles for both genes (Zahid et al., 2014). 
Although no similar studies have been reported for breast or other cancers, a similar polygenic 
approach can be instrumental in exploring the role of genetic polymorphisms among key estrogen-
metabolizing enzymes in precipitating hormonal cancers. 
 
Racial Disparity in Cancer Etiology and Estrogen Metabolism 
An important inclusion criterion in studies exploring the levels of estrogen-DNA adducts 
in cancers, high risk groups, and controls was Caucasian race. In fact, the estimation of risk using 
the Gayle model score only works for Caucasians. However, to the best of our knowledge, no 
comparative studies on estrogen-DNA adduct formation between cancer cases and controls in 
African-American (AA) or Asian populations have been reported in the literature. 
The incidence of breast cancer among AA women is slightly higher compared to the same 
among Caucasian women. Albeit, breast cancer in AA women represents a much aggressive form 
leading to a greater mortality (Alcaraz et al., 2016), and appearance of triple negative (for ER, PR, 
and HER2) breast cancer has been reported before menopause (DeSantis et al., 2016). On the other 
hand, Asian women typically report lower breast cancer incidences compared to the same among 
Caucasian or AA women (Parkin et al., 1992). 
In the light of such similar incidences yet a somewhat different etiology leading to higher 
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mortality, exploring estrogen metabolism in AA populations can be imperative in understanding 
the mechanistic basis of the racial comparisons and contrasts. To the best of our knowledge, the 
present literature lacks any such studies on estrogen metabolism and carcinogenesis in AA 
populations. Also, a similar polygenic approach discussed in the earlier section among Caucasian 
populations can be equally useful to explain any observed anomalies in estrogen metabolism in AA 
populations. Together, these might pave the way for exploring estrogen metabolism and its role in 
carcinogenesis among non-Caucasian populations. 
 
Estrogen Metabolism in Fuchs Endothelial Corneal Dystrophy (FECD) 
FECD is a late onset degenerative ocular disease that affects corneal endothelium of both 
eyes leading to gradual loss of vision (Friedenwald et al., 1925). Its incidence is roughly estimated 
as 1 in 2000 individuals although cross-sectional studies indicate European populations to be 
disproportionately affected (Zoega et al., 2006). FECD is considered a multifactorial genetic 
disorder whose molecular etiology is not fully understood, resulting in a lack of chemotherapeutic 
drugs. Owing to this fact, FECD is currently the leading cause of corneal transplantation surgeries 
in the U.S. per year (Gain et al., 2016). 
 In healthy eyes, the basement membrane (Descemet’s membrane) separates corneal stroma 
from aqueous humor (AH), whereas the corneal endothelial (CE) cells sitting on Descemet’s 
membrane act as pumps to maintain the clarity of corneal stroma. These CE cells are post-
mitotically arrested, therefore acute insults that cause DNA damage and induce apoptosis might 
shrink the threshold functional pool of CE cells --leading to influx of AH, corneal edema, and loss 
of clarity/vision. Indeed, hallmark features of FECD pathogenesis include CE cell loss, thickening 
of Descemet’s membrane, and focal outgrowths in the central cornea called guttae (Vogt, 1921) 
(Fig. 3). Both central corneal guttae formation and FECD have been reported to be higher among 
females (Wilson et al, 1988), and this skewed gender ratio is yet to be explained satisfactorily. 
Interestingly, sex hormones have been implicated in FECD pathobiology, although the present 
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literature lacks any definitive studies. 
 The pathology of FECD starts with the central cornea and gradually spreads peripherally 
(Doutch et al., 2012). On the other hand, the central cornea receives more UV light than the 
peripheral parts – thereby making exposure to UV a potential candidate to initiate FECD. UV 
exposure can differentially induce different cytochrome P450 enzymes (Katiyar et al., 2000), some 
of which play key roles in estrogen metabolism discussed earlier. Owing to a lack of protective 
histones and a greater extent of ROS-induced lipid peroxidation in the inner mitochondrial 
membrane, mitochondrial DNA (mtDNA) has been reported to be damaged more by estrogen 
metabolites than genomic/ nuclear DNA (nDNA) (Thomas and Roy, 2001). Furthermore, the ROS-
scavenger N-acetylcysteine (NAC) has been shown to restore estrogen metabolism balance and 
protect from the accumulation of genotoxic metabolites (Cavalieri and Rogan, 2016). Therefore, 
exploring the role of UV exposure – estrogen metabolism axis in precipitation of CE cell 
mitochondrial dysfunction and apoptosis can provide molecular insights into FECD etiology and 




















Fig. 3. FECD pathobiology schematic depicting the causative factors and key events. (Adapted 







A literature survey indicates estrogen metabolism disbalance might play a role in 
precipitating non-cancerous pathologies such as FECD, whereas accumulating evidence suggests 
estrogen genotoxicity is an endogenous pathway for initiation of multiple types of cancer among 
Caucasian populations; although the present literature lacks any correlation studies between 
estrogen metabolism and cancer initiation among non-Caucasian populations. Collectively, the 
disbalance in the said metabolism has been attributed to four critical enzymes, but another level of 
complexity lies in the fact that some of these enzymes are subjected to modulation by naturally 
occurring antioxidants or toxicants, whereas some manifest gain-of-function, loss-of-function or 
even missense mutation polymorphisms. Under such circumstances, this study aims to explore the 
role of estrogen metabolism in non-cancerous pathologies (FECD), in cancer initiation among non-
Caucasian populations (AA), and its modulation by environmental toxicants (As2O3) and naturally 



















Chapter 1: Estrogen Metabolism and Arsenic Trioxide 
 
Introduction 
Arsenic is the 20th most abundant element in the earth’s crust, and trivalent arsenic trioxide 
(As2O3) contaminates groundwater in many places, leading to arsenic poisoning or arsenicosis 
(Saha et al., 1999). Arsenic and inorganic arsenic compounds have been classified as IARC Group 
1 carcinogens (Straif et al., 2009), with lung, bladder, kidney and liver as the predominant targets. 
At the same time, As2O3 (Trisenox or ATO) is being used as a chemotherapy drug against acute 
promyelocytic leukemia (APL), where it selectively kills the leukemic cells but allows the proper 
development of regular blood cells (Soignet et al., 1998). Interestingly, arsenic has long been 
implicated in endocrine disruption. Target genes for glucocorticoids, androgens, 
mineralocorticoids, and progestin receptors have also been reported to be regulated by inorganic 
arsenic in a biphasic dose-response fashion (Bodwell et al., 2006). To address such documented 
carcinogenicity and putative endocrine disruption, the U.S. Environmental Protection Agency has 
set the Maximum Contaminant Level for As2O3 at 10 ppb (US EPA, 2001). 
The principal pathways implicated in As2O3-toxicity result from reactive oxygen species 
(ROS), oxidative DNA damage, and induction of apoptosis. Resveratrol, a well-known dietary 
stilbene, has been shown to protect normal human bronchial epithelial cells from As2O3-toxicity by 
maintaining glutathione homeostasis (Chen et al., 2015). Cardiotoxicity, a major side effect of using 
As2O3 for APL, could be ameliorated in Wistar rats by resveratrol, via maintenance of a balanced 
expression of the Nrf2-heme oxygenase (HO)1 pathway, and by promoting arsenic efflux from cells 
(Zhang et al., 2013). Employing similar mechanisms, resveratrol has been reported to protect from 
As2O3-induced nephrotoxicity in male Wistar rats (Zhang et al., 2014), and from hepatotoxicity in 
Chinese Dragon-Li cats (Zhang et al., 2014). Finally, research by at least one group has 
demonstrated the ability of inorganic arsenic to promote carcinogenesis via a non-estrogen receptor 
(ER)-mediated pathway: chronic exposure (18 weeks) to environmentally relevant 0.5 µM arsenite 
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promoted cancer cell phenotypes in human prostate epithelial stem/progenitor cells (WPE-stem) 
(Tokar et al., 2010), and in its isogenic parental RWPE-1 cells (30 weeks) (Achanzar et al., 2002).  
Chronic exposure (24 weeks) to low-level arsenite (500 nM) has also been reported to do the same 
thing in human breast epithelial cells (MCF10A) via overexpression of aromatase (Xu et al., 2014). 
To the best of our knowledge, no studies have explored any protective role of resveratrol on As2O3-
induced carcinogenesis via non-ER-mediated pathways. 
Estrogens have been implicated in the development of a variety of cancers. Several types 
of evidence suggest the role of estrogen in tumor development in an ER knock-out transgenic 
mouse model of breast cancer (Bocchinfuso  et al., 1999), as well as in the transformation of ERα-
negative breast epithelial cells (MCF10F) (Russo et al., 2003). To explain such receptor-
independent pathways for cancer initiation, it has been hypothesized that metabolism of 
estrogens/androgens generates catechol quinones that can react with DNA, leading to the formation 
of apurinic sites and mutations, to initiate oncogenic transformation (Cavalieri and Rogan, 2014). 
In high-risk groups and cancer patients (women: breast, ovarian, and thyroid; men: prostate and 
non-Hodgkin lymphoma), an imbalance in estrogen metabolism stems from irregular expression 
patterns of one or more of the four key estrogen-metabolizing enzymes: CYP19 or aromatase, 
CYP1B1, COMT, and NQO1 (Cavalieri and Rogan, 2014). Certain naturally occurring or synthetic 
compounds can alter the expression of some of these enzymes; e.g. TCDD can induce CYP1B1, 
whereas resveratrol antagonizes this effect. At the same time, resveratrol can induce NQO1 (Zahid 
et al., 2008). Pre-incubation with 25 μM resveratrol for 48 h significantly lowered the production 
of estrogen-DNA adduct formation in ERα-negative human breast epithelial MCF10F cells (Zahid 
et al., 2008). Therefore, in this study, the effects of As2O3 on the expression levels of key estrogen-
metabolizing enzymes (NQO1 and CYP1B1), and on the signaling molecule Nrf2, were studied in 
the presence or absence of 25 μM resveratrol in immortalized but non-transformed ERα-negative 




Cell lines and cell culture: For this study, the following immortalized but non-transformed ERα-
negative human breast epithelial cell lines were acquired from ATCC (Rockville, MD): 
1. MCF10A,  
2. MCF10F and  
3. MCF12F  
These cells were cultured in DMEM and Ham’s F12 growth medium (1:1; Invitrogen) 
supplemented with 5% fetal bovine serum (FBS), 20 ng/ml epidermal growth factor, 0.01 mg/ml 
insulin, 500 ng/ml hydrocortisone, 10 ng/ml cholera toxin and 100 μg/ml penicillin/streptomycin 
mixture. For assay purposes, estrogen-free medium was prepared using phenol red indicator-free 
DME/F12 medium (Invitrogen) and charcoal-stripped FBS and was supplemented as described 
above. Cells were grown or subjected to assays in flasks (25-150 mm2), 6 or 96-well plates in a 
humidified atmosphere containing 5% CO2 at 37ºC. 
Cytotoxicity: Upon exposure to varying concentrations of As2O3 and/or resveratrol, cell viability 
was determined by the MTT assay, which reflects the reduction of MTT to purple-colored formazan 
by dehydrogenase enzymes present in viable cells. Cells were seeded in a 96-well plate (seeding 
density: MCF10A 3000 cells per well, MCF12F 5000 cells per well) in estrogen- and phenol red 
indicator-free media and treated with 0.5 – 50 μM total concentration of As2O3 (Purity > 99.5%; 
Sigma-Aldrich, St. Louis, MO), 12.5 – 200 μM total concentration of resveratrol (Purity ≥ 98%; 
Cayman Chemical, Ann Arbor, MI), or 0.5 – 50 μM total concentration of As2O3 + 25 μM 
resveratrol for 2 time points (48 and 72 h). Finally, MTT (Calbiochem, San Diego, CA) was used 
to assess cell viability and corresponding IC50 values were compared. 
Protein Expression Studies: Expression levels of the key estrogen-metabolizing enzymes NQO1, 
CYP1B1, and CYP1A1, and of cell signaling protein Nrf2 were studied under different treatment 
regimens. Cells were seeded in a 6-well plate (seeding density: MCF10A and MCF10F 0.8X106 
cells per well, MCF12F 1X106 cells per well) in estrogen- and phenol red indicator-free media, and 
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treated with 0.5 – 5 μM concentration of As2O3 ± 25 μM resveratrol for 48 h. Following cell lysis 
with RIPA buffer containing 50 mM Tris-HCl pH 7.5, 1 mM EDTA pH 8.0, 150 mM NaCl, 10 mM 
MgCl2, 1% NP-40 and 0.005 µg/ml protease inhibitor cocktail (Roche Diagnostics, Basel, 
Switzerland), total protein was estimated by the Bradford assay, and 10-50 μg of total protein were 
resolved on a 7.5% polyacrylamide gel and transferred to PVDF membranes. The membranes were 
probed with anti-NQO1, anti-Nrf2 (Abcam, Cambridge, MA), anti-CYP1B1 (LSBio, Seattle, WA), 
anti-CYP1A1 (Sigma-Aldrich, St. Louis, MO) or anti-β-actin (Santa Cruz, Dallas, TX) primary 
antibodies overnight at 4°C and secondary antibodies for 1 h at room temperature. Detection was 
performed with ECL Western Blotting Detection Reagents (GE Healthcare/Amersham, Little 
Chalfont, UK). Densitometric analyses of Western blots were performed using Bio-Rad’s Image 
Lab™ software 4.1. Normalization was done with β-actin expression, and both the treatment and 
western blotting were performed three times to achieve statistical significance. 
Analysis of Estrogen-Metabolism: MCF10A cells were seeded in T75 flasks at 0.25X106 cells 
per T75 flask with 5 flasks per treatment. Following attachment, cells were pre-treated with 
estrogen- and phenol red indicator-free media for 48 hrs, and treatment was given with 5 μM As2O3 
or 25 μM resveratrol or both for 48hrs. Finally, treated cells were incubated for 24 hrs with fresh 
medium containing DMSO control, 10 μM 4-catechol estrogen or 25 μM estradiol to study the 
biological effect of As2O3 and resveratrol on estrogen metabolism. The collected media was stored 
in -80° freezer or was partially purified by using SPE phenyl cartridges, concentrated with a 
SpeedVac and lyophilized (Gaikwad et al., 2008). The lyophilized eluates were reconstituted in 50 
µl of methanol-water solution (1:1) and passed through a 5000 m.w. cut-off filter before 10 µl of 
each sample was subjected to ultraperformance liquid chromatography/tandem mass spectrometry 
(UPLC-MS/MS) analysis, carried out with a Waters Acquity UPLC system connected with a high 
performance Quattro Micro triple quadrupole mass spectrometer as previously described (Gaikwad 
et al., 2008). Resulting data were processed by using QuanLynx software (Waters) to quantify: 1. 
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Depurinating estrogen-DNA adducts, 4-OHE1(E2)-1-N3Ade, 4-OHE1(E2)-1-N7Gua, and 2-
OHE1(E2)-6-N3Ade; 2. 4- and 2-catechol estrogen metabolites 4-OHE1(E2) and 2-OHE1(E2); 3. 4- 
and 2-catechol estrogen methoxy conjugates 4-OCH3E1(E2) and 2-OCH3E1(E2); and 4. 4-catechol 
estrogen quinone conjugates 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, and 4-OHE1(E2)-2-NAcCys. 
Quantification of the estrogen compounds was provided by comparison to standard response curves 
for each compound. The precision of these analyses is provided by the limit of detection and 
coefficient of variation for the UPLC-MS/MS method, which were presented earlier (Gaikwad et 
al., 2008). All the study samples were analyzed in triplicates or duplicates.  
Among the standards, estrogen-3,4-quinone conjugates were synthesized by the reactions 
of estrogen quinones with reduced cysteine, N-acetylcysteine, or glutathione (Cao et al., 1998). 
Estrogen–DNA adducts were synthesized by following methods reported in the literature (Stack et 
al., 1996, Li et al., 2004, Zahid et al., 2006). All other analytical standards were purchased from 
Steraloids (Newport, RI). 
Statistical Analysis: To determine whether the differences observed were statistically significant 
or not, a 2-sample t-test was performed. Alpha was set at 0.05 for all statistical tests and data with 
















Results and Discussion 
25 μM Resveratrol Protected from the Cytotoxicity of As2O3: As2O3 exhibited cytotoxicity at 
both 48 and 72 hrs, with an IC50 at 1.45 μM for 48 hr treatment (Fig. 4.A), which is an 
environmentally significant exposure. However, the presence of resveratrol, which also has some 
cytotoxicity (Fig. 4.B) at 25 μM, reduced this cytotoxicity by shifting the survival curves to the 
right. The IC50 for combined 48 hr As2O3 and resveratrol treatment was 28.69 μM. The rightward 
shift in survival curve was lesser for 72 hr treatment compared to that for 48 hr treatment (Fig. 4.C). 
This indicates that the rescue effect from resveratrol was more pronounced at 48 hr. 
Both 25 μM Resveratrol and As2O3 Induced NQO1 and Nrf2 Expressions: As2O3, with or 
without 25 μM resveratrol, induced the enzyme NQO1 in a dose-dependent manner, but no additive 
or synergistic effects were observed (Figs. 5.A and 5.B). Resveratrol has been shown to act via the 
signaling molecule Nrf2, and NQO1 has been reported as a downstream gene of Nrf2 (Ungvari et 
al., 2010). This prompted us to study the effect of As2O3 on the expression level of Nrf2. As2O3, in 
both the presence and absence of 25 μM resveratrol, increased Nrf2 protein levels in a dose-
dependent fashion, but again no additive or synergistic effects were observed (Figs. 5.C and 5.D). 
Our finding is in accordance with a study in mouse hepatoma cell line hepa1c1c7, in which arsenic 
was shown to increase Nrf2 protein levels in a dose-dependent fashion, leading to a robust induction 
of NQO1 (He et al., 2006). Furthermore, in MCF10A cells, the degree of increase in Nrf2 protein 
levels was much greater for Nrf2 compared to that for NQO1, but this may stem from the fact that 
resting cells have a very low-level basal expression of Nrf2 (t1/2=10-20 mins) (Itoh et al., 2003). 
Similar disproportionate inductions of NQO1 and Nrf2 by As2O3 has been reported in male 















Fig. 4. Viability of MCF10A cells treated with As2O3 with and without resveratrol. (A) As2O3 
alone. (B) Resveratrol alone. (C) As2O3 + 25 μM Resveratrol. Data are presented as mean ± 
standard error of the mean cell survival (% of control) from six independent experiments (n=6) 
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Fig. 5. Induction of NQO1 (A & B) and Nrf2 (C & D) in MCF10A cells by As2O3 with and 
without resveratrol. (A) and (C) Representative images. (B) and (D) Quantitative data. Data 
are presented as mean ± standard error of the mean protein expression (% of control) from three 
independent experiments (n=3), X= Mean of two experiments. A † indicates significant difference 
(p<0.05) between As2O3 treatment groups and control whereas an * indicates significant difference 
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As2O3 Suppressed CYP1B1 Expression whereas 25 μM Resveratrol Rescued It: CYP1B1 is 
another key estrogen-metabolizing enzyme that is overexpressed in a variety of cancers, including 
breast, and is subject to regulation through both hormonal and a putative AhR pathway; the latter 
can be modulated by resveratrol (Spink et al., 1998). Previous studies on the male C57Bl/6 mouse 
heart have reported that 12.5 mg/kg As(III) induces CYP1B1 mRNA levels by 150% (Anwar-
Mohamed et al., 2012). We observed, however, that As2O3 treatment (0.5 – 5 μM) of human breast 
epithelial MCF10A cells caused repression of CYP1B1 protein in a dose-dependent manner. 
Resveratrol was earlier shown to downregulate TCDD-induced CYP1B1 expression in MCF10F 
cells (Lu et al., 2008). Interestingly, addition of 25 μM resveratrol rescued As2O3-suppressed 
CYP1B1 expression and kept it at a nearly constant level (Figs. 6.A and 6.B). To confirm this 
interesting observation, expression of CYP1B1 enzyme was further studied simultaneously in three 
different non-transformed cell lines derived from human breast epithelia, namely MCF10A, 
MCF10F and MCF12F cells. In this study, the cells were also treated with a higher dose of 7.5 µM 
As2O3. The repressive effect of As2O3 on CYP1B1 expression was less pronounced in MCF10F 
cells -- leaving little room for resveratrol to exert any rescue effect (Figs. 7.C and 7.D). 
Furthermore, such repressive effect of As2O3 on CYP1B1 expression was altogether absent in 
MCF12F cells (Figs. 7.E and 7.F). Collectively, these results suggest different degrees of 
modulatory effects of As2O3. 
One possibility is the differential cytotoxicity of As2O3, as we have observed between 
MCF10A and MCF12F cells (IC50 value for MCF10A was 1.45 µM for 48 hr treatment, whereas 
the same for MCF12F was 11.65 µM; Fig. 4.A vs. Fig. 8). As2O3 is not considered a ligand for 
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Fig. 6. Repression of CYP1B1 in MCF10A cells by As2O3 with and without resveratrol. (A) 
Representative image. (B) Quantitative data. Data are presented as mean ± standard error of the 
mean protein expression (% of control) from three independent experiments (n=3), X= Mean of 
two experiments. A † indicates significant difference (p<0.05) between As2O3 treatment groups and 
control whereas an * indicates significant difference (p<0.05) between one particular As2O3 
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Fig. 7. Expression of CYP1B1 by As2O3 with and without resveratrol. (A), (C) and (E) 
Qualitative images. (B), (D) and (F) Quantitative data. (A & B) MCF10A cells. (C & D) 
MCF10F cells. (E & F) MCF12F cells. Data are presented as protein expression (% of control) 












































































































Fig. 8. Viability of MCF12F cells treated with As2O3. Data are presented as mean ± standard 




























In conclusion, in the present study involving non-transformed breast epithelial MCF10A 
cells, 25 μM resveratrol was shown to ameliorate As2O3-induced cytotoxicity; with the beneficial 
effect being more prominent after 48 hr treatment. As expected, both As2O3 and resveratrol induced 
the expression of the catechol quinone-quenching enzyme NQO1, possibly via stabilizing the 
signaling protein Nrf2. Collectively, these results suggest that 25 μM resveratrol has the ability to 
modulate the effects of As2O3 on the expression of estrogen-metabolizing enzymes in MCF10A 
cells.  
Next, expression of key estrogen-metabolizing enzymes was studied from metabolic assay 
experiments in MCF10A cells in the presence of 5 µM As2O3 and/ or 25 µM resveratrol. When cells 
were grown for 48 hrs, the effects of As2O3 and/ or resveratrol on the expression of key estrogen-
metabolizing enzymes corroborated our earlier observations. Briefly, both As2O3 and resveratrol 
induced NQO1, with the former showing a stronger induction. This effect was also preserved when 
cells were grown for another 24 hrs without As2O3 or resveratrol (Fig. 9). As2O3 repressed CYP1B1 
whereas addition of resveratrol rescued it to some extent. However, this effect was not observed 
when cells were grown for another 24 hrs without As2O3 or resveratrol (Fig. 10). CYP1A1 
expression patterns roughly followed the same as for CYP1B1, but to much lesser extents (Fig. 11). 
The incubation with substrates E2 or 4-OHE2 for the final 24 hrs, however, yielded some interesting 
observations. Briefly, 4-OHE2 alone repressed CYP1B1 expression by 15% (Fig. 10). As CYP1B1 
activity generates 4-OHE2, this might be a defense mechanism employed by cells to handle surplus 
exogenous 4-OHE2. E2 alone induced CYP1A1 expression by ~50% (Fig. 11). As E2 is a substrate 
for CYP1A1, this might be a mechanism employed by cells to handle surplus exogenous E2. 
However, this might lead to greater activation of the 2-adduct formation pathway. Finally, 4-OHE2 
alone repressed NQO1 expression by 30% (Fig. 9). As NQO1 activity enables cells to prevent 
adduct formation from 4-OHE2, this repression might hamper cells’ ability to handle surplus 







Fig. 9. Expression of NQO1 in MCF10A cells subjected to 48 hr treatment with 5 µM As2O3 
and/or 25 µM resveratrol (X), 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol 
followed by 24 hr post-treatment growth without any As2O3 or resveratrol (-), 48 hr treatment 
with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 
(E2), or 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2). Data are presented as mean protein expression (% of 










Fig. 10. Expression of CYP1B1 in MCF10A cells subjected 48 hr treatment with 5 µM As2O3 
and/or 25 µM resveratrol (X), 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol 
followed by 24 hr post-treatment growth without any As2O3 or resveratrol (-), 48 hr treatment 
with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 
(E2), or 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2). Data are presented as mean protein expression (% of 










Fig. 11. Expression of CYP1A1 in MCF10A cells subjected to 48 hr treatment with 5 µM As2O3 
and/or 25 µM resveratrol (X), 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol 
followed by 24 hr post-treatment growth without any As2O3 or resveratrol (-), 48 hr treatment 
with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 
(E2), or 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2). Data are presented as mean protein expression (% of 






Finally, the levels of 20 estrogen metabolites including catechol estrogens, estrogen 
conjugates and DNA-adducts from MCF10A cells subjected to metabolic assay were analyzed. 
Both As2O3 and resveratrol, either singly or in combination, were observed to lower adduct 
formation – which might stem from their inducing effects on NQO1. However, some degree of 
activation is observed with the As2O3 + resveratrol combination which might stem from the rescue 
effect of resveratrol rendering As2O3 alone a better repressor for both CYP1B1 and CYP1A1 than 
that by the As2O3 + resveratrol combination (Fig. 12). Supporting evidence comes from the fact 
that increased catechol formation was observed with As2O3 treatment, either singly or in 
combination with resveratrol – which is again indicative of induced NQO1. However, as As2O3 
represses both CYP1B1 and CYP1A1 more than the As2O3 + resveratrol combination, less catechol 
formation from E2 was observed with As2O3 alone compared to the combination (Fig. 13). The 
surplus catechols, generated with As2O3 treatment, either singly or in combination with resveratrol, 
might lead to greater production of methoxy conjugates (Fig. 14), quinones and then quinone 

















Fig. 12. Depurinating adduct formation in MCF10A cells subjected to 48 hr treatment with 5 
µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 (A), or 
48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment 
with 10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the mean adduct 











Fig. 13. Occurrence of catechols in MCF10A cells subjected to 48 hr treatment with 5 µM 
As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 (A), or 48 hr 
treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 
10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the mean catechol 











Fig. 14. 4-Methoxy conjugate formation in MCF10A cells subjected to 48 hr treatment with 5 
µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 25 µM E2 (A), or 
48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment 
with 10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the mean methoxy 











Fig. 15. Estrogen-3,4-Quinone conjugate formation in MCF10A cells subjected to 48 hr 
treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 hr post-treatment with 
25 µM E2 (A), or 48 hr treatment with 5 µM As2O3 and/or 25 µM resveratrol followed by 24 
hr post-treatment with 10 µM 4-OHE2 (B). Data are presented as mean ± standard error of the 









Collectively, the oxidative insult of cells by As2O3 did prompt cells to activate their first 
line of defense, NQO1, which showed functional efficacy by lowering adduct formation and 
increasing catechol and conjugate formation. Interestingly, resveratrol at 25 µM, by its rescuing 
effects on CYP1B1 and CYP1A1, rendered the As2O3 + resveratrol combination little less effective 
than As2O3 alone in lowering estrogen-DNA adduct formation. Based on these studies, we cannot 
conclude resveratrol co-treatment with As2O3 has any beneficial roles on estrogen metabolism. 
However, resveratrol might be beneficial owing to its chemical properties as well as the protection 
from As2O3-cytotoxicity might stem from other cellular pathways. E2 and 4-OHE2 largely affected 
the expression of key estrogen-metabolizing enzymes in ways that might aid cells to restore the 
balance in estrogen metabolism. One striking observation was the repression of NQO1 by 4-OHE2 
(instead of induction), which might move the equilibrium of estrogen metabolism further away and 
might contribute to cellular carcinogenesis in response to 4-OHE2 exposure. However, this needs 
















Chapter 2: Estrogen Metabolism and Protective Antioxidants  
 
Introduction 
The imbalance of estrogen/androgen metabolism in high-risk groups and cancer patients 
stems from irregular expression patterns of one or more of the 4 key estrogen-metabolizing 
enzymes: CYP19 or aromatase, CYP1B1, COMT, and NQO1 (Singh et al., 2005). Certain naturally 
occurring or man-made compounds have the ability to induce or repress the expression of some of 
these key estrogen-metabolizing enzymes; e.g.  TCDD, a potent environmental carcinogen can 
induce CYP1B1, whereas resveratrol antagonizes this effect.  At the same time resveratrol can 
induce NQO1 independently (Lu et al., 2008). Our laboratory has shown that pre-incubation with 
resveratrol significantly lowers the production of estrogen-DNA adduct formation in MCF10F cells 
(Zahid et al., 2008). Using a cocktail of antioxidants like resveratrol and N-acetylcysteine, further 
such reduction was observed (Zahid et al., 2011). However, the limited bioavailability of 
resveratrol led to a search for more tolerable and efficacious antioxidants. 
Resveratrol is the most well-known stilbene, but studies on European populations have 
found PD to be the most abundant dietary stilbene (Zamora-Ros et al., 2008). PD or Piceid is 
extensively used in Chinese traditional medicine and is isolated from the roots of Japanese 
knotweed Polygonum cuspidatum (Fig. 16.A). It is also found in a variety of natural products such 
as grape juice and red wine, bark of Picea sitchensis, peanuts, hop cones, hop pellets, cocoa and 
chocolate products etc. It serves as a naturally-occurring precursor of resveratrol (Fig. 16.B), and 
the hydrolysis takes place within the intestinal lumen, enterocytes, and hepatocytes (Henry-Vitrac 
et al., 2006). However, there are 3 main differences: PD is more water-soluble than resveratrol, 
resveratrol uptake happens via passive diffusion whereas PD is via carrier-mediated active transport 
(Neves et al., 2012), and PD is more resistant to enzymatic oxidation than resveratrol. All these 
facts indicate that PD may lead to increased bioavailability of resveratrol in serum. However, this 










Fig. 16. (A) Japanese knotweed Polygonum cuspidatum, the most common natural source of 










Since the 1990’s, several studies have been carried out to explore the biological functions 
of PD. PD has been shown to have anti-inflammatory roles, which may stem from a reduction in 
pro-inflammatory cytokine IL-17 production (in a dose-dependent fashion) (Lanzilli et al., 2012), 
or from inhibition of pro-inflammatory NF-κB signaling (Ji et al., 2012). These anti-inflammatory 
effects enable PD to exert protective functions on several targets: pre-administration of PD for 5 
continuous days reversed CCl4-induced acute liver injury in mice (Zhang et al., 2012); and learning 
and memory functions improved in mice by neuro-protection (Li et al., 2012) etc. Several lines of 
studies have documented anti-tumorigenic effects of PD. It inhibited proliferation, induced S phase 
cell cycle arrest; and apoptosis of A549 and NCI-H1975 lung cancer cells (Zhang et al., 2014). PD, 
alone, or in a synergistic combination of a 3:1 molar ratio with resveratrol, arrested the cell cycle, 
and induced differentiation and apoptosis of Caco-2 human colorectal cancer cells (De Maria et al., 
2013). Both resveratrol and PD inhibited proliferative growth in mouse myoblast cells via estrogen 
receptor β and induction of mitochondrial manganese-dependent superoxide dismutase (MnSOD) 
(Robb et al., 2014). However, its effect in carcinogenesis via estrogen metabolism regulation is yet 
to be explored. 
Clearly, PD has chemical and physiological advantages over resveratrol, and this makes it 
a very suitable candidate for studying its effect on regulating estrogen metabolism and the net 
effects on carcinogenesis. This study aims to investigate this not only for PD alone, but also its 
combination with resveratrol, including the predicted synergistic combination; and tease out the 











Cell lines and cell culture: For this study, the following cell lines were acquired from ATCC 
(Rockville, MD): 
1. MCF10A (immortalized but non-transformed human breast epithelial),  
2. RWPE-1 (immortalized but non-transformed human prostate epithelial) 
MCF10A cells were cultured and subjected to assays as described in Chapter 2. RWPE-1 cells were 
cultured in RPMI-1640 growth medium (Invitrogen) supplemented with 10% fetal bovine serum 
(FBS) and 100 μg/ml penicillin/streptomycin mixture. For assay purposes, estrogen-free medium 
was prepared using phenol red indicator-free RPMI-1640 medium (Invitrogen) and charcoal-
stripped FBS and was supplemented as described above. Cells were grown or subjected to assays 
in flasks (25-150 mm2), and 6- or 96-well plates in a humidified atmosphere containing 5% CO2 at 
37ºC. 
Cytotoxicity: To carry out a systematic study of the effect of PD and resveratrol, whole cell 
cytotoxicity was studied in the model cells MCF10A and RWPE-1. Following pre-treatment with 
estrogen and phenol red indicator-free medium for 48 hrs, 3000 MCF10A cells or 10,000 RWPE-
1 cells were seeded per well in a 96-well plate and treated with 12.5 – 200 μM total concentration 
of compound for 3 time points (24, 48, and 72 hrs). Finally, MTT was used to assess cell viability. 
Protein Expression Studies: Expression levels of the key estrogen-metabolizing enzymes NQO1, 
CYP1B1, and CYP1A1 were studied under different treatment regimens. As earlier, cells were pre-
treated with estrogen and phenol red indicator-free medium for 48 hrs, and 0.8X106 MCF10A cells 
or 1.5X106 RWPE-1 cells were seeded per well in a 6-well plate for treatment with 12.5 – 200 μM 
total concentration of antioxidant compound(s) for 2 time points (48 and 72 hrs). Following cell 
lysis with RIPA buffer, total protein was estimated by the Bradford Assay, and 10-50 μg of total 
protein were analyzed for NQO1, CYP1B1, and CYP1A1 expression by western blotting. 
Densitometric analyses of Western blots were performed using Bio-Rad’s Image Lab™ software 
4.1. Normalization was done with β-actin expression, and both the treatment and western blotting 
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were performed three times to achieve statistical significance. 
Analysis of Estrogen-Metabolism: Both MCF10A and RWPE-1 cells were seeded in T75 flasks 
(seeding density: MCF10A 0.25X106 cells per T75 flask, RWPE-1 0.5X106 cells per T75 flask; 5 
flasks per treatment). Following attachment, cells were pre-treated with estrogen- and phenol red 
indicator-free media for 48 hrs, and treatment was given with 25 μM resveratrol or 25 μM PD for 
48 hrs. Finally, treated cells were incubated for 24 hrs with fresh medium containing DMSO 
control, 10 μM 4-OHE2 or 10 μM 4-OHE2 + antioxidant compounds (same concentration used in 
48 hr treatments) to study the biological effect of antioxidant compounds on estrogen metabolism. 
The collected media was analyzed by UPLC-MS/MS as described in the previous chapter for: 1. 
Depurinating estrogen-DNA adducts, 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua, 2. 4-
catechol estrogen metabolites 4-OHE1(E2), 3. 4-catechol estrogen methoxy conjugates 4-
OCH3E1(E2), and 4. 4-catechol estrogen quinone conjugates 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, 
and 4-OHE1(E2)-2-NAcCys.  
Statistical Analysis: To determine whether the differences observed were statistically significant 
or not, a 2-sample t-test was performed. Alpha was set at 0.05 for all statistical tests and data with 













Results and Discussion  
PD Is Safer than Resveratrol: In MCF10A cells subjected to 48 hr treatment, PD had an IC50 of 
approx. 200 µM whereas the same for resveratrol was approx. 50 µM. An approx. 4 times higher 
IC50 for PD than that for resveratrol for 48 hr treatment indicates PD is over-all safer compared to 
resveratrol (Fig. 17). RWPE-1 cells showed viability patterns similar to MCF10A cells when 
treated with resveratrol or PD. However, they seem more tolerant than MCF10A cells for either of 
the antioxidants (Fig. 18). 
Resveratrol Induced NQO1 more than PD: In MCF10A cells, almost all treatments (except very 
high doses of resveratrol) for both compounds induced NQO1 expression; and maximal induction 
was observed at 48 hr treatment for both compounds. However, resveratrol showed maximal 
induction at lower doses (12.5-25 µM), whereas PD increased the induction up to the highest dose 
studied (200 µM) (Fig. 19). 
Resveratrol Repressed CYP1B1 more than PD: On  the other hand, in MCF10A cells, both 
resveratrol and PD repressed CYP1B1 expression, but the degree of repression was much higher 
for resveratrol than for PD. Resveratrol almost silenced the expression of CYP1B1 at 50 µM, 
whereas PD lowered it to approx. 40% even at 200 µM (Fig. 20). 
Taken together, in MCF10A cells, PD was found to be safer than resveratrol, but also less 
efficacious in inducing the key estrogen-metabolizing enzyme NQO1 and repressing another key 















Fig. 17. Viability of MCF10A cells treated with (A) Resveratrol. (B) Polydatin. Data are 


































    
 
Fig. 18. Viability of RWPE-1 cells treated with (A) Resveratrol. (B) Polydatin. Data are 







































Fig. 19. NQO1 induction in MCF10A cells treated with resveratrol (A & B) or PD (C & D). 
(A) and (C) Representative images. (B) and (D) Quantitative data. Data are presented as mean 












Fig. 20. CYP1B1 repression in MCF10A cells treated with resveratrol (A & B) or PD (C & 
D). (A) and (C) Representative images. (B) and (D) Quantitative data. Data are presented as 









Next, expression of key estrogen-metabolizing enzymes was studied in metabolic assay 
experiments in RWPE-1 cells in the presence of 25 µM resveratrol or PD. When cells were grown 
for the final 24 hrs without any 4-catechol estrogen, the effects of resveratrol or PD on the 
expression of key estrogen-metabolizing enzymes in RWPE-1 cells somewhat corroborated our 
earlier observations in MCF10A cells. Briefly, both resveratrol and PD induced NQO1 in RWPE-
1 cells, and they were almost equally effective inducers. However, when cells were grown in the 
presence of 4-OHE2 ± antioxidants, PD showed a stronger induction than resveratrol (Fig. 21). 
Unlike in MCF10A cells, in RWPE-1 cells, PD showed greater repression of CYP1B1 than 
resveratrol (Fig. 22). On the other hand, resveratrol showed greater induction of CYP1A1 than PD 
(Fig. 23). However, when cells were grown in the presence of 4-OHE2 + antioxidant, PD exhibited 
marked induction on the expression of both CYP1B1 and CYP1A1 (Figs. 22 and 23).  
As observed in MCF10A cells, the incubation with 4-OHE2 alone or with 4-OHE2 + 
antioxidant for the final 24 hrs yielded some interesting observations. Briefly, 4-OHE2 alone 
repressed CYP1B1 expression by 30% (Fig. 22). As CYP1B1 activity generates 4-OHE2, this might 
be a defense mechanism employed by cells to handle surplus exogenous 4-OHE2. On the other 
hand, 4-OHE2 alone induced NQO1 expression by ~75% (Fig. 21). As NQO1 activity enable cells 
to neutralize quinones generated from 4-OHE2, this might be another defense mechanism employed 














Fig. 21. Expression of NQO1 in RWPE-1 cells subjected to 48 hr treatment with 25 µM 
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or 
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25 
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2 
+ 25 µM R/ PD). Data are presented as mean protein expression (% of control) from two 










Fig. 22. Expression of CYP1B1 in RWPE-1 cells subjected to 48 hr treatment with 25 µM 
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or 
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25 
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2 
+ 25 µM R/ PD). Data are presented as mean protein expression (% of control) from two 










Fig. 23. Expression of CYP1A1 in RWPE-1 cells subjected to 48 hr treatment with 25 µM 
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or 
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25 
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2 
+ 25 µM R/ PD). Data are presented as mean protein expression (% of control) from two 






Finally, the levels of 14 estrogen metabolites including catechol estrogens, estrogen 
conjugates and DNA-adducts from RWPE-1 cells subjected to metabolic assay were analyzed. 
More adduct formation was observed in the presence of 4-OHE2. Antioxidants, by inducing NQO1, 
lowered adduct formation, with PD being more effective than resveratrol. More such protection 
was observed when cells were grown in the presence of 4-OHE2 + antioxidants – which might stem 
from biological + chemical inhibition (Fig. 24). As observed in MCF10A cells, the supporting 
evidence in RWPE-1 cells also comes from the fact that increased catechol formation was 
concomitant with inhibition of adduct formation by antioxidant pre-treatment (Fig. 25). The surplus 
catechols, generated by antioxidant pre-treatment or treatment, might drive the greater production 
























Fig. 24. Depurinating adduct formation in RWPE-1 cells subjected to 48 hr treatment with 
25 µM resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or 
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25 
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2 
+ 25 µM R/ PD). Data are presented as mean adduct (4-OHE1/2-1-N7Gua + 4-OHE1/2-1-N3Ade) 










Fig. 25. Occurrence of catechols in RWPE-1 cells subjected to 48 hr treatment with 25 µM 
resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or 
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25 
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2 











Fig. 26. 4-Methoxy conjugate formation in RWPE-1 cells subjected to 48 hr treatment with 
25 µM resveratrol or 25 µM PD followed by 24 hr post-treatment growth without any PD or 
resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-
treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 µM resveratrol or 25 
µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM antioxidants (4-OHE2 
+ 25 µM R/ PD). Data are presented as mean 4-methoxy conjugate concentrations from two 










Fig. 27. Estrogen-3,4-Quinone conjugate formation in RWPE-1 cells subjected to 48 hr 
treatment with 25 µM resveratrol or 25 µM PD followed by 24 hr post-treatment growth 
without any PD or resveratrol (-), 48 hr treatment with 25 µM resveratrol or 25 µM PD 
followed by 24 hr post-treatment with 10 µM 4-OHE2 (4-OHE2), or 48 hr treatment with 25 
µM resveratrol or 25 µM PD followed by 24 hr post-treatment with 10 µM 4-OHE2 + 25 µM 
antioxidants (4-OHE2 + 25 µM R/ PD). Data are presented as mean 3,4-quinone conjugate 





Collectively, both the antioxidants studied did prompt RWPE-1 cells to activate its first 
line of defense, NQO1, which lowered adduct formation as well as increased catechol and 
conjugate formation. Although PD was found to be less efficacious than resveratrol in inducing the 
protective enzyme NQO1 or repressing the activating enzyme CYP1B1 in MCF10A cells, such a 
difference was largely non-existent in RWPE-1 cells – rendering PD equally effective as resveratrol 
in lowering estrogen-DNA adduct formation. This might be promising, as PD could be a less toxic 
alternative for resveratrol in chemo-preventing estrogen-induced cancer initiation in prostate cells. 



















Chapter 3: Estrogen Metabolism in African American Populations 
Introduction 
Exposure to estrogens has been associated with increased risk of breast (Kaaks et al., 2005) 
and ovarian cancer (Hunn and Rodriguez, 2012, Salehi et al., 2008, Sellers et al., 2005).  We 
previously published three studies showing increased ratios of estrogen-DNA adducts to estrogen 
metabolites and conjugates in Caucasian women at high risk for breast cancer or already diagnosed 
with the disease (Gaikwad et al., 2008, Gaikwad et al., 2009, Pruthi et al., 2012). We also found 
that the ratio of estrogen-DNA adducts to estrogen metabolites and conjugates is elevated in women 
diagnosed with ovarian cancer compared to women without ovarian cancer (Zahid et al., 2014).  
CYP1B1 is a key activating enzyme in the estrogen metabolic pathway that forms depurinating 
estrogen-DNA adducts because it catalyzes the oxidation of E1 and E2 to the 4-catechol estrogens, 
4-OHE1 and 4-OHE2 (Cavalieri and Rogan, 2011).  Studies of CYP1B1 polymorphisms and breast 
cancer have shown few significant associations, although a meta-analysis found that the Leu432Val 
polymorphism selected for this study significantly increased cancer risk (Liu et al., 2015). Studies 
of these same polymorphisms in ovarian cancer, however, provide evidence of an association when 
examined with other polymorphic enzymes such as COMT.  COMT is downstream of CYP1B1 
and an important protective enzyme that methylates catechol estrogens, preventing them from 
further oxidation to quinones that react with DNA (Fig. 1) (Cavalieri and Rogan, 2011). 
Approximately 25% of Caucasians are homozygous for the Val158Met (rs4680, AA) 
polymorphism in COMT, resulting in 4- to 5-fold lower activity (Dawling et al., 2001). Women 
with two copies of the low-activity SNP for COMT plus two copies of the high-activity SNP 
(rs1056836, GG) for CYP1B1 are 6-fold more likely to have ovarian cancer than women with 
normal activity alleles (Zahid et al., 2014). In addition, COMT polymorphisms have been 
associated with ovarian cancer when combined with other polymorphic enzymes in the catechol 
estrogen pathway (Sellers et al., 2005, Delort et al., 2008, Holt et al., 2007).    
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To date, no study has examined the consequences in African-American (AA) women of 
having a combination of at-risk variants of these genetic polymorphisms in relation to levels of 
estrogen metabolites, estrogen conjugates and depurinating estrogen-DNA adducts in breast cancer. 
Breast cancer presents somewhat differently in AA women compared to Caucasian women. From 
2010-2015 the incidence of breast cancer in AA women was slightly higher in AA women than in 
Caucasian women, but mortality was significantly higher in AA women (Alcaraz et al., 2016). 
Malignant breast tumors in AA women are more likely to be negative for ER, PR and HER2 
(DeSantis et al., 2016). These triple negative tumors are more likely to appear before menopause 
in AA women (Dietze et al., 2015). Since breast cancer presents somewhat differently in AA women 
compared to Caucasian women, it appeared important to discover whether estrogen metabolism 
and formation of depurinating estrogen-DNA adducts is also different. In this pilot study we began 
to test the hypotheses that AA women with breast cancer: (1) have a significantly higher ratio of 
estrogen-DNA adducts relative to estrogen metabolites and conjugates than AA women without 
breast cancer and (2) are more likely to carry a combination of the high activity CYP1B1 allele and 
the low activity COMT allele than AA women without breast cancer. A polygenic approach is more 
likely to produce a better understanding of the role of metabolic genes on the formation of DNA 















The study protocol was approved by the Institutional Review Board at the University of 
Nebraska Medical Center (UNMC). 
Study Population. Urine and saliva samples were collected at one event, the annual Celebration 
of Life luncheon sponsored by My Sister’s Keeper, a breast cancer support organization for AA 
women in Omaha, NE. Subjects self-identified as having been diagnosed with breast cancer or not 
having been diagnosed with breast cancer. Each completed an informed consent form before 
collecting a spot urine sample of approximately 50 ml and a saliva sample of approximately 2 ml 
in an Oragene tube (Rylander-Rudqvist et al., 2006). Control samples were obtained from 25 
women without breast cancer, and 19 women with breast cancer provided urine samples; two of the 
control samples could not be analyzed. Among the same women, saliva from all 25 control women 
yielded useful DNA, while 17 of the women with breast cancer provided saliva that yielded DNA. 
Sample collection. Approximately 50 ml of urine was obtained in a urine specimen cup containing 
1mg/ml ascorbic acid (to prevent oxidation of catechol estrogen metabolites). Urine samples were 
aliquoted, frozen and stored at -80C until analysis. Thus, each analytical sample was thawed only 
once prior to analysis. A saliva sample (~ 2 ml) was collected from each subject in an Oragene 
collection tube, which was stored at 3C until purification of DNA (Zahid et al., 2014).  
Analysis of estrogen compounds. A 2-ml aliquot of each urine sample was processed and 
subjected to UPLC-MS/MS analysis, as discussed in previous chapters. Resulting data were used 
to quantify the estrogen metabolites, conjugates and DNA adducts. All the study samples were 
analyzed in triplicates in a blinded fashion. The ratio of adducts to their respective metabolites and 




The estrogen metabolites include 2-OHE1(E2) and 4-OHE1(E2). The conjugates include 2-
OCH3E1(E2), 4-OCH3E1(E2), 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, and 4-OHE1(E2)-2-NAcCys. 
The adducts include 4-OHE1(E2)-1-N3Ade, 4-OHE1(E2)-1-N7Gua, and 2-OHE1(E2)-6-N3Ade.  
The ratio was multiplied by 1000 to avoid decimal points and zeroes. 
The concentration of each of the compounds and the ratio of depurinating N3Ade and 
N7Gua adducts to the sum of their respective estrogen metabolites and conjugates in each urine 
sample provides a ratio, which reflects the degree of imbalance in estrogen metabolism that may 
lead to cancer initiation (Gaikwad et al., 2008). Mean differences in the DNA adduct ratio were 
compared using the t-test.   
Sample Collection-SNPs. Oragene collection tubes were used for self-collection of saliva, 
stabilization, transportation, storage and genomic DNA purification (Rylander-Rudqvist et al., 
2006). DNA samples were genotyped using TaqMan assays (CYP1B1, C_3099976_30; COMT, 



















Results and Discussion 
The subjects in this study ranged in age from 41-77 years (median, 56) for controls and 
from 43-75 years (median, 65) for cases. The 19 women diagnosed with breast cancer had an 
estrogen-DNA adduct ratio (x 1000) of 92.4 ± 46.4, while the 23 women not diagnosed with breast 
cancer had a significantly lower ratio of 38.5 ± 18.9 (p < 0.001, Fig. 28). These results are similar 
to those observed previously with Caucasian women (Gaikwad et al., 2008, Gaikwad et al., 2009, 
Pruthi et al., 2012). In the previous studies, the ratio was significantly higher in both women with 
breast cancer and those at high risk for the disease, suggesting that formation of depurinating 
estrogen-DNA adducts plays a role in the initiation of breast cancer. In this first set of samples from 
AA women, we did not know whether control women were at normal or high risk for breast cancer. 
Nonetheless, AA women with breast cancer appear to metabolize estrogens and form depurinating 
estrogen-DNA adducts similarly to Caucasian women. 
Despite the small number of participants, we also collected saliva for isolation of genomic 
DNA and genotyped CYP1B1 (Val432Leu, rs1056836), an estrogen activating enzyme, and COMT 
(Val158Met, rs4680), an estrogen protective enzyme (Fig. 1). The two polymorphisms were in 
Hardy-Weinberg equilibrium in the study population (CYP1B1: χ2 = 2.58, p = 0.11; COMT: χ2 = 
0.58, p = 0.45). Allele frequencies for these two SNPs are similar to that reported in dbSNP for AAs 
(Table 1). We did not see an association of CYP1B1 (Val432Leu, rs1056836) and COMT 
(Val158Met, rs4680) SNPs with the ratio of DNA adducts or breast cancer. Using a polygenic 
approach with possible genotype combinations between COMT and CYP1B1, we also did not see 
any significant associations with DNA adduct ratios (p = 0.54) or breast cancer (p = 0.81). In larger 
studies, the CYP1B1 Val432Leu SNP, which increases its activity, was associated with breast 
cancer in AA women (Kato et al., 2009, Haddad et al., 2015). One possible confounder is that AA 
women have been reported to have lower frequencies of the COMT Val158Met SNP than Caucasian 










Fig. 28. Mean ratio and standard deviation of urinary depurinating estrogen-DNA adducts to 
estrogen metabolites and conjugates for AA women diagnosed with breast cancer (cases) or 










Table 1. Association of CYP1B1 and COMT polymorphisms with DNA adduct ratios and 







Although the number of subjects was too small to obtain useful information about CYP1B1 
and COMT activity in estrogen metabolism in these women, the estrogen-DNA adducts ratios in 
the breast cancer cases and controls were similar to those previously observed in Caucasian women 
(Gaikwad et al., 2008, Gaikwad et al., 2009, Pruthi et al., 2012). These results are consistent with 
the hypothesis that formation of estrogen-DNA adducts may be a critical factor in the etiology of 
breast cancer in AA women. A larger, more comprehensive study of estrogen metabolism and DNA 
adduct formation in AA women is warranted. 
A similar pilot study, albeit with even smaller sample size, was performed for AA men 
diagnosed with prostate cancer, at high risk (HR) but not diagnosed with cancer, and not diagnosed 
with cancer (control). As shown in the Fig. 29 inset, the mean ratio for the control group (26.6 ± 
63.4) was lower than the same for the HR group (43.3 ± 29) and the cancer group (80.3 ± 48.3). 
However, the extremely small sample sizes for the HR and cancer groups make the standard 




















Fig. 29. Ratios of urinary depurinating estrogen-DNA adducts to estrogen metabolites and 
conjugates for individual AA men diagnosed with prostate cancer (solid black), at high risk 
but not diagnosed with cancer (HR; patterned black), and not diagnosed with cancer (solid 







Taken together, these pilot studies indicated AA women with breast cancer, and AA men at 
high risk for or with prostate cancer might have higher estrogen-DNA adduct ratios than the 
controls; and the lack of statistical significance in the study with men suffers from extremely small 
sample sizes. This suggests that estrogen metabolism might be out of balance, and the formation of 
estrogen-DNA adducts may exert a critical role in breast cancer initiation in AA populations – 
which is in accordance with our earlier observations in Caucasian populations. However, no 
associations between the CYP1B1 and COMT genotypes studied and adduct ratios for breast cancer 



















Chapter 4: Estrogen Metabolism in FECD 
Introduction 
Way back in 1910, Ernst Fuchs first reported a debilitating disorder of the posterior cornea, 
which was subsequently referred to as Fuch’s Corneal Dystrophy (FCD). Early research indicated 
FCD only affects corneal endothelium, or human corneal endothelial cells (HcEnCs), hence the 
name was changed to FECD (Vogt, 1921). Although the clinical symptoms of FECD vary, there 
are certain salient features: the characteristic blurry morning vision is reported by patients mostly 
in their fifth and sixth decades of life, it’s slow-progressing (Friedenwald et al., 1925), bilaterally 
symmetrical, and sex-linked, with women 2-4 times more susceptible than men (Wilson et al, 
1988). In the US, approximately 4 percent of people over the age of 40 suffer from late-onset FECD, 
and it is currently the leading cause of corneal transplantation surgeries in the U.S. and developed 
world (Gain et al., 2016). 
 In healthy eyes, post-mitotically arrested hexagonal HcEnCs sit on the basement membrane 
of the cornea (Descemet’s membrane) and maintain the clarity of corneal stroma. The central 
cornea receives more UV light than the peripheral parts, and FECD has been reported to start with 
the central cornea, which then spreads peripherally (Doutch et al., 2012). Exposure to UV and 
concomitant oxidative stress have been implicated in DNA damage and induction of endothelial-
to-mesenchymal transition (EMT) in HcEnCs – which leads to thickening of Descemet’s 
membrane, extracellular matrix deposition in the form of pro-fibrotic focal outgrowths called 
guttae, corneal edema, and eventual loss of vision (Fig. 3).  
 Although the present literature lacks any explanation for the skewed gender ratio for FECD 
prevalence, a role for sex hormones has been postulated. Interestingly, UV exposure can 
differentially induce the key enzymes involved in estrogen metabolism (Katiyar et al., 2000), 
whereas the main protecting enzyme involved in estrogen metabolism, NQO1, has also been shown 
to prevent EMT. In a menadione (MN)-induced oxidative stress model in HcEnCs, our collaborator 
Dr. Ula Jurkunas at Harvard Medical School, Boston, MA, United States, has observed MN to 
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induce DNA damage, upregulation of EMT markers, and rosette formations characteristic to FECD 
(Katikireddy et al., 2018). MN is metabolized to menadiol by NQO1. On the other hand, NQO1 
has been reported to be repressed in both FECD and in MN-treatment (Fig. 30). To recapitulate 
FECD, the same study also used NQO1 KO cells where a heightened cytotoxicity to MN and 
apoptosis were observed. A quest to identify novel chemotherapeutic preventions for FECD has 
shown promising results with ROS-quencher NAC and NQO1-inducer sulforaphane, both of which 
have been shown to lessen oxidative stress and inhibit EMT. Present literature as well as previous 
chapters strongly implicate the role of a disbalanced estrogen metabolism in DNA-damage and 
cancer initiation, which could also be prevented to some extent by NAC (Cavalieri and Rogan, 
2016) and NQO1 inducers. Considering such striking parallels, exploring estrogen metabolism 
balance in FECD and correction of any said disbalance with naturally occurring compounds might 
provide molecular insights into FECD etiology and might potentiate the use of chemotherapeutic 



















Fig. 30. Repression of NQO1 by menadione in HCEnC-21T cells. (A) Representative gel 
image. (B) Quantitative data. Data are presented as mean ± standard error of the mean protein 
expression from three independent experiments (n=3), with control taken as unit. A * indicates a 
significant difference (p < 0.05) whereas a *** indicates a highly significant difference (p < 0.001) 










Generation of NQO1+/+ and NQO1 KO Cells (at Harvard): To abrogate the expression of 
NQO1 in HCEnC-21T cells, the NQO1 locus was targeted for a Crispr-Cas9 mediated excision by 
transfection of 2 μg of either NQO1 Double Nickase plasmid (sc-400326-NIC, Santa Cruz) or 
Control Double Nickase plasmid (sc-437281, Santa Cruz) in low passage HCEnC-21T cells. 
Analysis of Estrogen-Metabolism: NQO1+/+ and NQO1 KO HCEnC-21T cells were seeded in 
T75 flasks (seeding density: 1X106 cells per T75 flask, 4 flasks per treatment). Following 
attachment, cells were pre-treated with estrogen- and phenol red indicator-free media for 48 hrs, 
and treatment was given with 8.5 μM MN or 3.75 μM 4-OHE2 or 8.5 μM MN + 3.75 μM 4-OHE2 
or 8.5 μM MN + 3.75 μM 4-OHE2 + 25 μM NAC for 24 hrs (MN, 4-OHE2, and MN + 4-OHE2 
treatment concentrations were optimized following cell viability assays summarized in Fig. 31). 
The bathing media were pooled for every treatment and collected media was analyzed by UPLC-
MS/MS (at UNMC) as described in the previous chapters for: 1. Depurinating estrogen-DNA 
adducts, 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua, 2. 4-catechol estrogen metabolites 4-
OHE1(E2), 3. 4-catechol estrogen methoxy conjugates 4-OCH3E1(E2), and 4. 4-catechol estrogen 
quinone conjugates 4-OHE1(E2)-2-SG, 4-OHE1(E2)-2-Cys, and 4-OHE1(E2)-2-NAcCys.  
Statistical Analysis: To determine whether the differences observed were statistically significant 
or not, a 2-sample t-test was performed. Alpha was set at 0.05 for all statistical tests and data with 















Fig. 31. Viability of HCEnC-21T cells treated with (A) MN. (B) 4-OHE2. (C) MN + 4-OHE2. 
Data are presented as mean ± standard error of the mean cell survival (%) from six independent 








Results and Discussion 
The levels of 14 estrogen metabolites including catechol estrogens, estrogen conjugates 
and DNA-adducts from wild type and NQO1 KO HCEnC-21T cells subjected to metabolic assay 
were analyzed. The data shows that MN co-treatment increased adduct [sum of 4-OHE1(E2)-1-
N3Ade and 4-OHE1(E2)-1-N7Gua] formation (Fig. 32) while lowering 4-methoxy conjugate 
formation (Fig. 33). As MN represses NQO1, this might lead to a surplus of non-neutralized 
quinones, which might lead to the formation of more DNA-adducts. Less formation of 4-methoxy 
conjugates would stem from the same lower NQO1 expression. However, MN co-treatment did not 
cause much difference in estrogen-3,4-quinone conjugate formation (Fig. 34). 
Next, effects of both MN and NAC treatment were studied in the presence and absence of 
any functional NQO1 enzyme. In agreement with our findings discussed in the previous paragraph, 
MN did increase adduct [sum of 4-OHE1(E2)-1-N3Ade and 4-OHE1(E2)-1-N7Gua] formation (Fig. 
35) while lowering 4-methoxy conjugate formation (Fig. 36) in NQO1 wild type cells. In the same 
cells, co-treatment with MN and NAC lowered adduct formation (Fig. 35) with a concomitant 
increase in estrogen-3,4-quinone conjugate formation (Fig. 37). Interestingly, co-treatment of 
NQO1 wild type cells with MN and NAC further lowered 4-methoxy conjugate formation (Fig. 


















Fig. 32. Depurinating adduct formation in HCEnC-21T cells subjected to 24 hr treatment 
with 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2. Data are presented as mean ± 
standard error of the mean adduct (4-OHE1/2-1-N7Gua + 4-OHE1/2-1-N3Ade) concentrations from 














Fig. 33. 4-Methoxy conjugate formation in HCEnC-21T cells subjected to 24 hr treatment 
with 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2. Data are presented as mean ± 















Fig. 34. Estrogen-3,4-Quinone conjugate formation in HCEnC-21T cells subjected to 24 hr 
treatment with 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2. Data are presented 
as mean ± standard error of the mean 3,4-quinone conjugate concentrations from five independent 














Fig. 35. Depurinating adduct formation in wild type (NQO1 +/+) and NQO1 knock out 
(NQO1 -/-) HCEnC-21T cells subjected to 24 hr treatment with 3.75 μM 4-OHE2 or 8.5 μM 
menadione + 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2 + 25 μM NAC. Data 
are presented as mean ± standard error of the mean adduct (4-OHE1/2-1-N7Gua + 4-OHE1/2-1-














Fig. 36. 4-Methoxy conjugate formation in wild type (NQO1 +/+) and NQO1 knock out 
(NQO1 -/-) HCEnC-21T cells subjected to 24 hr treatment with 3.75 μM 4-OHE2 or 8.5 μM 
menadione + 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2 + 25 μM NAC. Data 
are presented as mean ± standard error of the mean 4-Methoxy conjugate concentrations from six 














Fig. 37. Estrogen-3,4-Quinone conjugate formation in wild type (NQO1 +/+) and NQO1 
knock out (NQO1 -/-) HCEnC-21T cells subjected to 24 hr treatment with 3.75 μM 4-OHE2 
or 8.5 μM menadione + 3.75 μM 4-OHE2 or 8.5 μM menadione + 3.75 μM 4-OHE2 + 25 μM 
NAC. Data are presented as mean ± standard error of the mean 3,4-Quinone conjugate 








Taken together, this suggests that NAC might be helpful in ameliorating MN-induced DNA 
damage. This is particularly important in NQO1 KO cells as these cells represent a better model 
for FECD. Such observations, coupled with the ability of NAC to prevent EMT, make NAC a very 
promising therapeutic modality for FECD. However, this needs to be supported with in vivo model-
based studies. Also, it would be interesting to explore whether NQO1-inducers like sulforaphane 
or resveratrol can provide any restoration from MN-induced estrogen metabolism disbalance, what 
the degree of such protection (if any) is, and if these compounds can be used synergistically with 






















 In order to explain the receptor-independent pathway of cancer initiation by estrogens, our 
laboratory formulated the central hypothesis that metabolism of endogenous or environmental 
estrogens/androgens generates catechol quinones that can react with DNA, leading to the formation 
of apurinic sites, which in turn generate mutations, and initiate oncogenic transformation. Over the 
past decade, numerous types of in vitro and in vivo evidence have established a link between 
estrogen genotoxicity and carcinogenesis. However, these studies were either only mono-racial, or 
the restoration of the dynamic balance in estrogen metabolism using naturally occurring 
compounds were not very useful for human trials. At the same time, recent studies have also 
implicated estrogen metabolism in non-cancerous pathologies like FECD. Therefore, to move 
forward towards prevention of pathologies, the role of estrogen metabolism in FECD, in cancer 
initiation in AA populations, and its modulation by environmental toxicants, As2O3, and the 
naturally occurring antioxidants PD and resveratrol were explored. 
 In accordance with the existing literature, As2O3 was observed to induce cytotoxicity in 
human breast epithelial non-transformed MCF10A cells, which was partially ameliorated by 25 
μM resveratrol. The oxidative insult of cells by As2O3 did prompt cells to activate their first line of 
defense, NQO1, via Nrf2 stabilization; and both these effects were also shared by 25 μM 
resveratrol. Interestingly, As2O3 suppressed CYP1B1 expression whereas 25 μM resveratrol 
restored it to basal levels -- rendering the As2O3 + resveratrol combination a little less effective than 
As2O3 alone in lowering estrogen-DNA adduct formation. Based on these observations, we cannot 
conclude that resveratrol co-treatment with As2O3 has any beneficial roles on estrogen metabolism. 
However, resveratrol might be beneficial owing to its chemical properties as well as the protection 
from As2O3-cytotoxicity might stem from other cellular pathways. 
The comparative study between two naturally occurring antioxidants PD and resveratrol 
found PD to be safer than resveratrol. Both the compounds induced NQO1, albeit in varying 
degrees, leading to lowering of adduct formation. In human breast epithelial non-transformed 
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MCF10A cells, PD was found to be less efficacious than resveratrol in inducing the protective 
enzyme NQO1 or repressing the activating enzyme CYP1B1, although such a difference was 
largely non-existent in human prostate epithelial non-transformed RWPE-1 cells – rendering both 
the antioxidants equally effective in lowering estrogen-DNA adduct formation. This indicates that 
PD could be a less toxic alternative for resveratrol in chemo-preventing estrogen-induced cancer 
initiation in prostate cells. 
Epidemiological studies indicated AA women with breast cancer do have higher estrogen-
DNA adduct ratios than the controls, whereas AA men at high risk for or with prostate cancer might 
have higher estrogen-DNA adduct ratios than the controls. This suggests loss of the balance in 
estrogen metabolism might be instrumental in breast and prostate cancer initiation in AA 
populations – which is in accordance with our earlier observations in Caucasian populations. 
However, no associations between CYP1B1 and COMT genotypes studied and adduct ratios for 
breast cancer were observed in AA women. This calls for larger study populations and/ or a shift in 
the genetic polymorphisms studied. 
Based on the studies in the MN-induced in vitro FECD model, it was observed NAC might 
be helpful in ameliorating estrogen-DNA adduct formation. The finding that such protection from 
NAC happens even in absence of any functional NQO1 makes it an even more promising 
therapeutic modality for FECD, as NQO1 KO cells represent a better model for FECD. In vivo 
model-based evidence can potentiate such claims, whereas exploration of similar chemopreventive 
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